Published in Am J Pathol on March 01, 2001
Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer | NCT02343614
A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila) (2011) 1.70
COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer (2004) 1.59
Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol (2002) 1.46
Preventive but not curative efficacy of celecoxib on bladder carcinogenesis in a rat model. Mediators Inflamm (2011) 1.42
Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol (2006) 1.14
Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Res (2005) 1.07
COX-2 and cancer: a new approach to an old problem. Br J Pharmacol (2001) 1.02
Monomethylarsonous acid produces irreversible events resulting in malignant transformation of a human bladder cell line following 12 weeks of low-level exposure. Toxicol Sci (2010) 1.01
Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer (2006) 0.99
FGFR1-induced epithelial to mesenchymal transition through MAPK/PLCγ/COX-2-mediated mechanisms. PLoS One (2012) 0.98
Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target. J Cancer Res Clin Oncol (2004) 0.97
Nuclear localization of COX-2 in relation to the expression of stemness markers in urinary bladder cancer. Mediators Inflamm (2012) 0.95
Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines. World J Gastroenterol (2003) 0.93
Chemoprevention of bladder cancer. World J Urol (2006) 0.90
Identification of human cyclooxegenase-2 inhibitors from Cyperus scariosus (R.Br) rhizomes. Bioinformation (2014) 0.88
Decreased xanthine oxidoreductase is a predictor of poor prognosis in early-stage gastric cancer. J Clin Pathol (2006) 0.86
Pathobiology and chemoprevention of bladder cancer. J Oncol (2011) 0.84
New therapeutic targets in the management of urothelial carcinoma of the bladder. Res Rep Urol (2013) 0.81
Metformin represses bladder cancer progression by inhibiting stem cell repopulation via COX2/PGE2/STAT3 axis. Oncotarget (2016) 0.81
COX-2 overexpression in resected pancreatic head adenocarcinomas correlates with favourable prognosis. BMC Cancer (2014) 0.80
Inhibition of bladder tumor growth by chitooligosaccharides in an experimental carcinogenesis model. Mar Drugs (2012) 0.79
Chemopreventive property of dietary ginger in rat urinary bladder chemical carcinogenesis. World J Urol (2006) 0.78
Regulation of the prostaglandin pathway during development of invasive bladder cancer in mice. Prostaglandins Other Lipid Mediat (2008) 0.78
Celecoxib for the prevention of nonmuscle invasive bladder cancer: results from a matched control study. Ther Adv Urol (2015) 0.77
Early bladder cancer: concept, diagnosis, and management. Int J Clin Oncol (2006) 0.77
Cyclooxygenase-2 expression in bladder cancer and patient prognosis: results from a large clinical cohort and meta-analysis. PLoS One (2012) 0.76
Expression of cyclooxygenase-2 (COX-2) in pituitary tumours. Med Sci Monit (2012) 0.75
The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol (1998) 7.61
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med (2000) 7.54
Cyclooxygenase in biology and disease. FASEB J (1998) 7.17
Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A (1997) 4.84
Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res (1995) 4.52
Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res (1998) 3.20
Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res (1997) 2.99
Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res (1998) 2.92
Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst (1998) 2.26
Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst (1998) 2.09
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res (1998) 1.94
Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology (2000) 1.84
Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res (2000) 1.84
Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol (1999) 1.83
Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res (2000) 1.67
Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res (1999) 1.58
Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res (1998) 1.46
Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol (2000) 1.42
The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur J Cancer (1995) 1.32
Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin Cancer Res (2000) 1.31
Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res (2000) 1.30
Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms. Mol Carcinog (1999) 1.23
Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol (2000) 1.12
Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res (1998) 1.12
High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol (2000) 1.09
Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or -2. FEBS Lett (1999) 0.98
Aspirin, NSAIDs, and digestive tract cancers. Cancer Metastasis Rev (1994) 0.94
Increased expression of cyclooxygenase-2 protein in rat urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Carcinogenesis (1999) 0.92
Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin Investig Drugs (1999) 0.87
Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. Am J Vet Res (2000) 0.83
Increased expression of cyclooxygenase-2 protein in rat lung tumors induced by N-nitrosobis(2-hydroxypropyl)amine. Cancer Lett (2000) 0.78
Recognition of a bacterial adhesion by an integrin: macrophage CR3 (alpha M beta 2, CD11b/CD18) binds filamentous hemagglutinin of Bordetella pertussis. Cell (1990) 4.47
Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res (1998) 2.92
Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer (2007) 2.36
Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res (1995) 2.31
Allograft response in vitro. Transplant Rev (1972) 2.20
Reduction of inflammation, tissue damage, and mortality in bacterial meningitis in rabbits treated with monoclonal antibodies against adhesion-promoting receptors of leukocytes. J Exp Med (1989) 2.18
Hepatosplenic candidiasis in patients with acute leukemia: incidence and prognostic implications. Clin Infect Dis (1997) 2.08
Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut (2005) 2.07
Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer (1986) 1.91
Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer (2003) 1.86
Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol (2009) 1.78
Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum. Clin Chem (1999) 1.52
Absence of the major sialoglycoprotein in the membrane of human En(a--) erythrocytes and increased glycosylation of band 3. J Biol Chem (1976) 1.46
Proliferation of B and T cells in mixed lymphocyte cultures. J Exp Med (1973) 1.46
Gastrointestinal cancer-associated antigen CA 19-9 in histological specimens of pancreatic tumours and pancreatitis. Br J Cancer (1986) 1.45
Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA. Br J Cancer (1986) 1.44
The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer (1994) 1.44
[Treatment of depression and cost efficiency. The cost of a tablet is a poor indicator seen from a socioeconomic perspective]. Lakartidningen (2000) 1.39
Stimulation of density-inhibited cell cultures by insulin. J Cell Physiol (1973) 1.37
CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res (2002) 1.36
Bmi-1 expression predicts prognosis in squamous cell carcinoma of the tongue. Br J Cancer (2010) 1.33
Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. Br J Cancer (1998) 1.32
Serum CA 50 as a tumor marker in pancreatic cancer: a comparison with CA 19-9. Int J Cancer (1987) 1.30
Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer (1993) 1.28
The nature of cell wall-derived inflammatory components of pneumococci. Pediatr Infect Dis J (1989) 1.27
A whole-blood lymphocyte stimulation test for the diagnosis of human tularemia. J Infect Dis (1984) 1.26
Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases. Br J Cancer (1991) 1.25
Allograft immunity in vitro. VI. Autonomy of T lymphocytes in target cell destruction. Scand J Immunol (1973) 1.25
Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin Cancer Res (2001) 1.24
Neuraminidase stimulates division and sugar uptake in density-inhibited cell cultures. Nat New Biol (1972) 1.22
Allergic rhinitis and the common cold--high cost to society. Allergy (2009) 1.22
Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer (2013) 1.21
Separation of T and B lymphocytes by preparative cell electrophoresis. Eur J Immunol (1972) 1.19
Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9. Br J Cancer (1989) 1.18
Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. Acta Oncol (1997) 1.17
Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol (2006) 1.14
Elevation of free beta subunit of human choriogonadotropin and core beta fragment of human choriogonadotropin in the serum and urine of patients with malignant pancreatic and biliary disease. Cancer Res (1992) 1.11
High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer. Br J Cancer (2009) 1.11
Fractionation of mouse T and B lymphocytes by preparative cell electrophoresis. Efficiency of the method. Cell Immunol (1973) 1.10
Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma. Br J Cancer (2004) 1.09
Transfilter induction of kidney tubles: correlation with cytoplasmic penetration into nucleopore filters. J Embryol Exp Morphol (1974) 1.09
Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases. Br J Cancer (1986) 1.06
17q12-21 amplicon, a novel recurrent genetic change in intestinal type of gastric carcinoma: a comparative genomic hybridization study. Genes Chromosomes Cancer (1997) 1.06
Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer (2011) 1.06
Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer (2001) 1.05
Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer. Oncology (2005) 1.03
Carcinoma of the stomach and its heredity in young patients. Scand J Gastroenterol (1988) 1.02
Thymus-dependent and thymus-independent lymphocyte separation: relation to exposed sialic acid on cell surface. Science (1972) 1.01
Presence of high-level DNA copy number gains in gastric carcinoma and severely dysplastic adenomas but not in moderately dysplastic adenomas. Cancer Genet Cytogenet (1998) 1.01
Prognostic value of Ki-67 expression, ploidy and S-phase fraction in patients with pancreatic cancer. Anticancer Res (1996) 1.01
Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer? Br J Cancer (1995) 1.01
Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung. Br J Cancer (1998) 1.00
Expression of tenascin-C in intraductal carcinoma of human breast: relationship to invasion. Eur J Cancer (1998) 1.00
High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer. Br J Cancer (2011) 0.99
Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA. Br J Cancer (1987) 0.98
Histopathology of localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993. Scand J Urol Nephrol Suppl (1994) 0.97
Poor prognosis associated with elevated serum CA 19-9 level in advanced colorectal carcinoma, independent of DNA ploidy or SPF. Eur J Cancer (1993) 0.96
STn and prognosis in breast cancer. Oncology (2001) 0.95
Surgery in mandibular condylar hyperplasia. J Maxillofac Surg (1985) 0.95
Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases. Br J Cancer (1987) 0.95
Anaplastic and poorly differentiated thyroid carcinoma: therapeutic strategies and treatment outcome of 52 consecutive patients. Oncology (2011) 0.94
Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9. Anticancer Res (1996) 0.94
Hepatosplenic yeast infection in patients with acute leukemia: a diagnostic problem. Clin Infect Dis (1994) 0.94
Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Int J Cancer (1997) 0.94
Tissue expression of human chorionic gonadotropin beta predicts outcome in colorectal cancer: a comparison with serum expression. Int J Cancer (2001) 0.94
The red cell phenotype En(a-) and anti-Ena: serological and physicochemical aspects. Vox Sang (1969) 0.94
Preoperative assessment of proliferative activity and hormonal receptor status in carcinoma of the breast: a comparison of needle aspiration and needle-core biopsies to the surgical specimen. Diagn Cytopathol (1996) 0.93
Serum trypsinogen-2 and trypsin-2-alpha(1)-antitrypsin complex in malignant and benign digestive-tract diseases. Preferential elevation in patients with cholangiocarcinomas. Int J Cancer (1996) 0.93
A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer. Br J Cancer (1998) 0.93
Concentrations of human choriogonadotropin, its beta-subunit, and the core fragment of the beta-subunit in serum and urine of men and nonpregnant women. Clin Chem (1992) 0.93
Effects of supplemental alpha-tocopherol and beta-carotene on urinary tract cancer: incidence and mortality in a controlled trial (Finland). Cancer Causes Control (2000) 0.92
Are morphogenetic tissue interactions mediated by transmissible signal substances or through cell contacts? Nature (1976) 0.92
Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer. Oncology (1996) 0.92
Expression of laminin in pancreatic neoplasms and in chronic pancreatitis. Am J Surg Pathol (1984) 0.92
DNA synthesis and cell generation cycle during determination and differentiation of the metanephric mesenchyme. Dev Biol (1983) 0.92
Evidence that the MCC-APC gene region in 5q21 is not the site for susceptibility to hereditary nonpolyposis colorectal carcinoma. Cancer Res (1992) 0.91
Effect of intraperitoneal bupivacaine on pain after laparoscopic cholecystectomy. Acta Anaesthesiol Scand (1995) 0.91
Retinoic acid induces signal transducer and activator of transcription (STAT) 1, STAT2, and p48 expression in myeloid leukemia cells and enhances their responsiveness to interferons. Cell Growth Differ (1997) 0.91
Increased expression of cyclooxygenase-2 in malignant pheochromocytomas. J Clin Endocrinol Metab (2001) 0.91
Do membrane filters prevent cell contacts? Nature (1972) 0.90
Mk and Mg: some serological and physicochemical observations. Vox Sang (1969) 0.90
Localization and development of bombesin/GRP-like immunoreactivity in the rat central nervous system. Ann N Y Acad Sci (1988) 0.90
On the intracellular uptake of neuraminidase. Exp Cell Res (1967) 0.90
MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer. J Clin Pathol (2006) 0.90
Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin. Clin Chem (1998) 0.90